Article Details

Kyn Nabs $49M to Target Metabolism and Beat Other Cancer Drug Combos

Retrieved on: 2017-12-13 19:26:15

Tags for this article:

Click the tags to see associated articles and topics

Kyn Nabs $49M to Target Metabolism and Beat Other Cancer Drug Combos. View article details on hiswai:

Excerpt

<div>Kyn Therapeutics is designing drugs to block some of those escape routes, and today announced a $49 million Series A round from <b>Atlas Venture</b> and OrbiMed Advisors. Kyn, based in Cambridge, MA and founded in 2016, is taking aim at a metabolic reaction in immune and cancer cells that tumors ...</div>

Article found on:

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up